Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
MWN-AI** Summary
Unicycive Therapeutics, Inc. announced today that the FDA has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), a novel oral phosphate binder designed to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. This acceptance is categorized as a Class II complete response, initiating a six-month review period, with a Prescription Drug User Fee Act (PDUFA) action date set for June 27, 2026. CEO Shalabh Gupta expressed optimism about the resubmission, highlighting the company's preparation for a potential launch later this year to provide critical treatment options for CKD patients.
The NDA submission is supported by a comprehensive set of data from three clinical studies, demonstrating OLC's efficacy and safety. The FDA has reported no concerns regarding the preclinical, clinical, or safety data from the original NDA submission.
Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to fund operations into 2027. This financial stability supports ongoing activities to prepare for the anticipated commercial launch of OLC.
OLC employs proprietary nanoparticle technology, allowing for reduced pill size and number, potentially enhancing patient adherence compared to existing treatments. The company is seeking FDA approval through the 505(b)(2) regulatory pathway, backed by a strong patent portfolio that provides exclusivity until at least 2031, with potential extensions to 2035.
Hyperphosphatemia is a critical health issue for CKD patients, often requiring medication for management. Unicycive’s innovative approach aims to improve treatment effectiveness and patient compliance in managing this serious condition.
MWN-AI** Analysis
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has announced the FDA's acceptance of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), a key milestone for the company as it targets a PDUFA date of June 27, 2026. With the company's current cash position of $41.3 million, it appears well-positioned to sustain operations well into 2027, paving the way for strategic commercial preparations ahead of OLC's anticipated launch.
Investors should be cautiously optimistic regarding Unicycive's pipeline and potential market entry. The acceptance of the NDA indicates that the FDA has found OLC's submission robust, encompassing supportive clinical data from three studies without raising safety concerns. OLC represents a unique treatment for hyperphosphatemia in chronic kidney disease patients, a significant and growing market driven by the increasing prevalence of kidney issues among the aging population and patients on dialysis.
OLC's formulation promises advantages in patient adherence due to its lower pill burden—an appealing attribute that may differentiate it from existing therapies. However, potential investors should consider the inherent risks in clinical-stage biotech ventures, including the uncertainties surrounding health outcomes, regulatory hurdles, and market competition.
With the upcoming review timeline established by the FDA, interest may build, and positive developments could lead to an upward push in Unicycive’s stock price. Nonetheless, investors should remain vigilant regarding company performance, competition, market approval dynamics, and financial stability.
In summary, while the current developments signal promising prospects for Unicycive Therapeutics, thorough due diligence is advised. The combination of a solid cash runway, innovative therapeutic product, and a well-defined regulatory pathway can create potential upside, but investors should stay alert to the various risks in the biotechnology landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026
- Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Agency has deemed the OLC resubmission to be a Class II complete response which has a six-month review period from the date of resubmission and set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2026.
“We are pleased that the agency has promptly accepted the resubmission of our NDA for OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year, to help provide an important treatment option to patients with chronic kidney disease (CKD) on dialysis who continue to struggle with hyperphosphatemia.”
The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies as well as chemistry, manufacturing and controls (CMC) data. The FDA did not raise any concerns regarding OLC’s preclinical, clinical, or safety data included in the original NDA submission.
The Company ended 2025 with an unaudited position of $41.3 million in cash, cash equivalents, and short-term investments, which permits continued advancement of OLC commercial launch activities and a cash runway into 2027.
About Oxylanthanum Carbonate (OLC)
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ**
What steps is Unicycive Therapeutics Inc. (UNCY) taking to ensure a successful launch of oxylanthanum carbonate (OLC) by the June 27, 2026 PDUFA target date, considering their current cash position of $41.3 million?
With OLC's resubmission receiving a Class II designation from the FDA, what specific commercial or marketing strategies does Unicycive Therapeutics Inc. (UNCY) plan to implement ahead of the anticipated product launch?
How does Unicycive Therapeutics Inc. (UNCY) plan to manage potential risks, such as regulatory delays or safety concerns, while navigating the commercial preparation activities for OLC before the PDUFA target date?
Given the competitive landscape for phosphate binders in CKD treatment, what advantages does Unicycive Therapeutics Inc. (UNCY) believe OLC holds over existing alternatives that may impact its market adoption following FDA approval?
**MWN-AI FAQ is based on asking OpenAI questions about Unicycive Therapeutics Inc. (NASDAQ: UNCY).
NASDAQ: UNCY
UNCY Trading
4.6% G/L:
$6.82 Last:
162,932 Volume:
$6.51 Open:
